beta
IA Trial Radar
O estudo clínico NCT06573593 para Alopecia Areata, Janus Kinase Inhibitors está em recrutamento. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui.
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study 150 Dados de vida real

Em recrutamento
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT06573593 é um estudo observacional para Alopecia Areata, Janus Kinase Inhibitors. Seu status atual é: em recrutamento. O estudo começou em 29 de julho de 2024 e pretende incluir 150 participantes. Coordenado por Second Affiliated Hospital, School of Medicine, Zhejiang University e deve ser concluído em 31 de dezembro de 2026. Essas informações foram atualizadas no ClinicalTrials.gov em 27 de agosto de 2024.
Resumo
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disea...Mostrar mais
Título oficial

Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study

Condições médicas
Alopecia AreataJanus Kinase Inhibitors
Outros IDs do estudo
  • 20240699
Número NCT
NCT06573593
Data de início (real)
2024-07-29
Última atualização postada
2024-08-27
Data de conclusão (estimada)
2026-12-31
Inscrição (estimada)
150
Tipo de estudo
Observacional
Status
Em recrutamento
Braços / Intervenções
Grupo de participantes/BraçoIntervenção/Tratamento
Tofacitinib treated group
In the real-world settings, patients with AA treated with tofacitinib.
Tofacitinib
In the real-world settings, patients with AA treated with tofacitinib.
Baritinib treated group
In the real-world settings, patients with AA treated with baritinib.
Baricitinib
In the real-world settings, patients with AA treated with Baricitinib.
Ruxolitinib treated group
In the real-world settings, patients with AA treated with ruxolitinib
Ruxolitinibe
In the real-world settings, patients with AA treated with Ruxolitinib.
Upadacitinib treated group
In the real-world settings, patients with AA treated with upadacitinib.
Upadacitinib
In the real-world settings, patients with AA treated with Upadacitinib.
Abrocitinib treated group
In the real-world settings, patients with AA treated with abhicitinib.
Abrocitinib
In the real-world settings, patients with AA treated with Abrocitinib.
Ritlecitinib treated group
In the real-world settings, patients with AA treated with ritlecitinib.
Ritlecitinib
In the real-world settings, patients with AA treated with Ritlecitinib.
Desfecho primário
Medida de desfechoDescrição da medidaPrazo
Mean SALT
Reduction of Severity of Alopecia Tool (SALT) score compared with baseline
at week 24
SALT50
Percentage of patient with more than 50% improvement in SALT score
at week 24
SALT75
Percentage of patient with more than 70% improvement in SALT score
at week 24
Desfecho secundário
Medida de desfechoDescrição da medidaPrazo
Mean SALT
Reduction of Severity of Alopecia Tool (SALT) score compared with baseline
at week 12, 36, 48, 56
SALT50
Percentage of patient with more than 75% improvement in SALT score
at week 12, 36, 48, 56
SALT75
Percentage of patient with more than 50% improvement in SALT score
at week 12, 36, 48, 56
Safety profile
Any adverse events including infection, hypohepatia, thrombus, gastrointestinal reaction and any other system events.
at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56
Assistente de participação
Critérios de elegibilidade

Idades elegíveis
Criança, Adulto, Idoso
Idade mínima
2 Years
Sexos elegíveis
Todos
  • Patients with alopecia areata between 2 to 18 years old
  • Patients diagnosed with alopecia areata according to AA guideline
  • AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months

  • Patients had previously received hair implants
  • Other alopecia
  • Other diseases may induce alopecia including psoriasis, lichen planus, et al.
  • Unable to estimate SALT score at baseline or at follow-up
  • Patients are participating in other clinical trials
Second Affiliated Hospital, School of Medicine, Zhejiang University logoSecond Affiliated Hospital, School of Medicine, Zhejiang University
Contato central do estudo
Contato: Ru Dai, MD, 15982215914, [email protected]
Contato: Wu, [email protected]
1 Locais do estudo em 1 países

Zhejiang

Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, 310009, China
Ru Dai, Ph.D, Contato, 86 15982215914, [email protected]
Em recrutamento